- Investor's Business Daily•2 hours ago
The biotech group hit a seven-month high Wednesday before reversing after Hillary Clinton attacked drug pricing again.
- Barrons.com•7 hours ago
Gabelli & Co. On Monday, Pfizer announced that it had agreed to acquire Medivation for $81.50 per share in cash, or $14 billion of total enterprise value. The price represents a 21% premium to Medivation’s (MDVN) previous closing share price. Pfizer (PFE) hosted a conference call after the announcement.
Yesterday, we highlighted six stocks that the folks at Citigroup contend could be buyout targets following Pfizer's (PFE) $14 billion purchase of Medivation (MDVN). Today, Gabelli's Jing He offers four ...
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||81.55 x 200|
|Ask||87.78 x 200|
|Day's Range||81.55 - 87.98|
|52wk Range||55.00 - 133.62|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||224.02|
|Avg Vol (3m)||1,086,101|
|Dividend & Yield||N/A (N/A)|